EXIT-RIF: Evaluating the Xpert Impact on Tuberculosis – RIFampicin Resistance
EXIT-RIF is a before/after cohort study comparing treatment outcomes of patients diagnosed with rifampicin resistant TB by Xpert MTB/RIF or culture-based susceptibility method. The study started in February 2012.
Study Team Introduction
EXIT-RIF is a unique collaboration between several entities:
University of North Carolina
Annelies Van Rie, Colleen Hanrahan, Chris Lippincott
University of the Witwatersrand
Lesley Scott, Ian Sanne, Wendy Stevens Francesca Conradie ,Yara Lima
Stellenbosch University
Rob Warren, Paul Van Helden, Marianna de Kock
National Institute of Health
Gail Jacobs, Dikoe Makhene
Free State Site
Eugenne Elliot, Tina Wojno, S. Kabane
Eastern Cape Site
Cindy Hayes, Leilani Novem, Zonwabele Merile, Sr. Makaluza
Gauteng Site
Natalie Beylis, Pedro Da Silva, Parastu Meidany, Anionia Barnard